Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection
Open Access
- 28 April 2020
- journal article
- editorial
- Published by American Society for Microbiology in mBio
- Vol. 11 (2)
- https://doi.org/10.1128/mbio.00398-20
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.Keywords
This publication has 21 references indexed in Scilit:
- Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor BlockersmBio, 2015
- Angiotensin-converting enzyme 2/angiotensin-(1–7)/Mas axis prevents lipopolysaccharide–induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF–κB pathwaysScientific Reports, 2015
- Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modificationsBiochemical Pharmacology, 2015
- A Practical Treatment for Patients With Ebola Virus DiseaseThe Journal of Infectious Diseases, 2014
- Role of Claudin-5 in the Attenuation of Murine Acute Lung Injury by SimvastatinAmerican Journal of Respiratory Cell and Molecular Biology, 2014
- Imbalance Between Pulmonary Angiotensin-Converting Enzyme and Angiotensin-Converting Enzyme 2 Activity in Acute Respiratory Distress SyndromePediatric Critical Care Medicine, 2013
- Do viral infections mimic bacterial sepsis? The role of microvascular permeability: A review of mechanisms and methodsAntiviral Research, 2011
- Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin‐(1–7) or an angiotensin II receptor antagonistThe Journal of Pathology, 2011
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- LOSARTAN PREVENTS SEPSIS-INDUCED ACUTE LUNG INJURY AND DECREASES ACTIVATION OF NUCLEAR FACTORκB AND MITOGEN-ACTIVATED PROTEIN KINASESShock, 2009